Finance Watch: PTC Raises $1bn In Evrysdi Royalty Deal Weeks After Latest Layoffs
Abivax Launches 19th US Biopharma IPO Of 2023
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.